塔姆-霍斯法尔蛋白
生物
肾
突变体
分子生物学
远曲小管
炎症
细胞生物学
肾脏疾病
内分泌学
信使核糖核酸
内科学
细胞内
HEK 293细胞
核糖核酸
基因剔除小鼠
基因沉默
突变
癌症研究
寡核苷酸
作者
Sebastian Sjöström,Marta Mariniello,Guglielmo Schiano,Jennifer L. Lake,Sara Botta,Alyssa C. Hill,Jonathan Hall,Olivier Devuyst
摘要
Autosomal dominant tubulointerstitial kidney disease (ADTKD) arises from gain-of-toxic-function mutations in the UMOD gene coding for uromodulin, the most abundant protein excreted in normal urine. Mutant uromodulin accumulates in the cells lining the thick ascending limb (TAL) of the loop of Henle, leading to intracellular aggregates, cellular stress, and kidney damage. Here, we demonstrate that an antisense gapmer oligonucleotide (ASO) designed against the representative c.553C > A (p.R185S) UMOD mutation produced allele-selective silencing of the mutant messenger RNA and protein in kidney cells. Short-term administration of a murine ASO analogue in the established Umod R186S/+ mouse model of ADTKD suppressed uromodulin and lowered tubular damage, whereas a non-targeting scrambled control was inactive. After a 4-week treatment, ASO accumulation in the Umod R186S/+ kidneys reached ∼320 000 copies per TAL cell, quantified using a sensitive splint-ligation assay. The ASO treatment suppressed premature mutant uromodulin and its toxic aggregates in Umod R186S/+ kidneys, whereas it had no effects on wild-type uromodulin in Umod +/+ kidneys. Notably, the ASO improved tubular function and decreased kidney tubulointerstitial inflammation in Umod R186S/+ mice. This work offers a roadmap for antisense therapy to treat ADTKD-UMOD and substantiates the therapeutic potential of ASOs in disorders of the kidney tubule.
科研通智能强力驱动
Strongly Powered by AbleSci AI